Novo Nordisk: Reimbursement Milestones and Pill Approval Signal New Growth Levers, But Stock Remains Under Pressure

Novo Nordisk secures French reimbursement and EU oral Wegovy nod, but shares plunge 35% as US competition and cash-pay reliance overshadow near-term outlook.

Novo Nordisk is navigating a stark dichotomy. On one hand, the Danish pharma giant has secured landmark reimbursement for its weight-loss drugs in France, a positive EU regulatory opinion for its oral Wegovy pill, and an expanded adolescent approval in India. On the other, its shares have shed more than a third of their value over the past year, as competitive pressures in the US and a heavy reliance on cash-pay patients cloud the near-term outlook.

The stock closed last week at €39.45, up about 1% on the day but still down over 35% year-to-date. That puts the market capitalization at roughly $203bn and the trailing twelve-month price-to-earnings ratio at around 10.4 — a dramatic discount to Novo Nordisk's historical average of 26.

French Reimbursement Could Unlock a Billion-Euro Market

In a move that breaks new ground for the obesity treatment landscape, France will become the first EU member state to introduce a permanent public reimbursement system for anti-obesity medicines. Starting in mid-June 2026, Novo Nordisk's Wegovy and Eli Lilly's Mounjaro will be covered for patients with severe obesity — those with a body mass index of at least 40, or 35 with at least one weight-related comorbidity.

The standard reimbursement rate is 65%, though most patients are expected to achieve full coverage through supplementary insurance. The French government estimates annual costs of roughly €100m for about one million eligible patients. Until now, patients were paying around €300 out of pocket each month for Wegovy. The decision paves the way for a significantly larger addressable market in Western Europe.

Meanwhile, India's drug regulator CDSCO approved Wegovy for adolescents aged 12 and older weighing more than 60kg, to be used alongside diet and exercise. The approval, granted on May 28, 2026, came a year after the drug's adult launch in India and mirrors the FDA's 2023 pediatric nod. Novo Nordisk is targeting the rising prevalence of childhood obesity in the country.

Oral Wegovy Nears EU Launch After Strong Trial Data

The European Medicines Agency's human medicines committee has recommended approval of a 25mg oral semaglutide formulation for weight management and cardiovascular risk reduction, alongside a higher-dose 7.2mg injectable version of Wegovy. The recommendation is based on the phase 3 OASIS 4 trial, in which participants achieved an average weight loss of 16.6%, with over a third losing at least 20% of their body weight.

It marks the first time an oral GLP-1 drug has received a positive EU opinion for obesity. The final decision rests with the European Commission, and Novo Nordisk expects to launch the pill in selected markets outside the US in the second half of 2026. Within the US, where the oral Wegovy has been on sale since January, demand has been strong: more than 2m prescriptions have been written to date.

Competitive Pressure Intensifies in the US Formulary Arena

Yet Novo Nordisk's grip on the pharmacy channel is loosening. Eli Lilly's daily oral obesity drug Foundayo (orforglipron) received US approval on April 1, and pharmacy benefit manager CVS Caremark added it to its formulary effective June 1. At the same time, CVS will reinstate Lilly's injectable Zepbound as a preferred option from October, ending a period when Wegovy enjoyed exclusive preferred status. While Novo Nordisk's Wegovy products retain preferred placement, the company no longer commands an unrivalled position on the formulary.

The changing dynamics are reflected in the stock's performance: shares are down 12.5% since the start of the year. The dividend yield now stands at roughly 4%, and the relative strength index of 47.6 signals a neutral reading — neither oversold nor overbought.

The Cash-Pay Puzzle

Novo Nordisk's own disclosures on the Deutsche Bank conference offered a glimpse into an unusual market dynamic for its oral semaglutide. Some 90% of prescriptions currently flow through the cash-pay channel, meaning patients pay out of pocket without insurance coverage. That contrasts sharply with the typical pattern for prescription drugs, where reimbursement drives uptake. For investors, the pace at which that cash-pay share declines and public reimbursement expands in key markets will be the critical gauge of Novo Nordisk's growth trajectory.

As the company juggles a promising pipeline, new regulatory wins in Europe and Asia, and a more contested US landscape, the next few quarters will test whether the current valuation represents an opportunity or a value trap.